





# VISHNU PRAKASH R PUNGLIA LIMITED

Registered Office: Unit No. 3, 5 Floor, B-wing, Trade Star Premises Co-operative Society Limited, Village Kondivita, Mathuradas Vasani Road, Near Chakala Metro Station, Andheri (East), Mumbai - 400059, Maharashtra, India. Tel: +91 22 40164020; Website: https://www.vprp.co.in; Corporate Identity Number: L45203MH2013PLC243252

## Statement of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2024

Particulars	For the Quarter ended			Year ended	
	March 31, 2024	December 31, 2023	March 31, 2023	March 31, 2024	March 31, 2023
	(Refer Note 3)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
Total Income From Operation	6,572.06	2,420.50	4,557.03	14,738.65	11,684.04
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	907.02	230.99	540.09	1,645.18	1,224.39
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	907.02	230.99	540.09	1,645.18	1,224.39
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	671.34	173.69	399.09	1,221.85	906.43
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	668.21	175.50	403.89	1,222.15	913.17
Equity Share Capital	1,246.44	1,246.44	934.44	1,246.44	934.44
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year				5,964.20	2,210.63
Basic EPS & Diluted EPS (INR)	5.39	1.39	4.27	10.95	10.41

**Notes:**

- The above statement of financial results for the quarter and year ended March 31, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 27, 2024. The audited Financial Results have been reviewed by the Statutory Auditors of the Company. The statutory auditors of the Company have expressed an unqualified opinion on the audited financial results for the year ended March 31, 2024.
- The above is an extract of the detailed format of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2024 filed with the Stock Exchanges on May 27, 2024 under Regulation 33 of SEBI (listing obligations and other disclosure requirements) Regulations, 2015. The full format of the aforementioned financial results are available on the stock exchange websites (www.nseindia.com & www.bseindia.com) and the Company's website (www.vprp.co.in)
- The figures for the quarters ended March 31, 2024 are balancing figures between audited figure for the full financial year ended on March 31, 2024 and the unaudited published year to date figures upto the third quarter of the financial year.

For and on behalf of Board of VISHNU PRAKASH R PUNGLIA LIMITED  
 Sd/-  
**Manohar Lal Punglia**  
 Managing Director  
 (DIN : 02161961)

Date: May 28, 2024  
 Place: Jodhpur

# KANORIA CHEMICALS & INDUSTRIES LIMITED

"KCI PLAZA", 6TH FLOOR, 23C, ASHUTOSH CHOWDHURY AVENUE, KOLKATA-700 019  
 CIN : L24110WB1960PLC294910  
 WEBSITE : WWW.KANORICHEM.COM PHONE NO. +91 33 4031 3200

## EXTRACT OF STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2024

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended	Quarter ended
		31.03.2024	31.03.2024	31.03.2023	31.03.2024	31.03.2024	31.03.2023
1.	Total Income from operations	14,770	57,853	15,889	36,175	1,47,672	44,486
2.	Profit before Finance Costs, Depreciation & Amortisation, Exceptional Items and Tax	584	3,213	111	2,932	7,198	2,303
3.	Net Profit/(Loss) for the period (before Tax and Exceptional Item)	(194)	(87)	(694)	206	(3,354)	(301)
4.	Net Profit/(Loss) for the period before Tax (after Exceptional Item)	(194)	(329)	(694)	206	(3,596)	(301)
5.	Net Profit/(Loss) for the period (after Tax and Exceptional Item)	74	(112)	(469)	(1,569)	(5,528)	(90)
6.	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after Tax) after non-controlling interest]	45	(118)	(470)	(1,439)	(4,922)	(45)
7.	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after Tax) after non-controlling interest]	45	(118)	(470)	(849)	(3,357)	(150)
8.	Equity Share Capital	2,185	2,185	2,185	2,185	2,185	2,185
9.	Other Equity	-	61,742	-	-	57,942	-
10.	Earnings Per Share (Face Value INR 5/- each) - Basic & Diluted	0.18	(0.25)	(1.07)	(2.12)	(8.79)	(0.35)

**Notes:**

- The Company does not have any Extraordinary Item to report.
- The above is an extract of the detailed format of Financial Results for the quarter and year ended 31st March 2024, filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Full format of the Financial Results is available on the Stock Exchanges websites, www.bseindia.com, www.nseindia.com and on the Company's website at www.kanoricheem.com

For and on behalf of the Board  
 Sd/-  
**R.V. Kanoria**  
 Chairman & Managing Director  
 (DIN:00003792)

Place : New Delhi  
 Date : 28th May, 2024

# CANARA ROBECO

## Canara Robeco Mutual Fund

Investment Manager : Canara Robeco Asset Management Co. Ltd.  
 Construction House, 4th Floor, 5, Walchand Hirachand Marg, Ballard Estate, Mumbai 400 001.  
 Tel.: 6658 5000 Fax: 6658 5012/13 www.canararobeco.com CIN No.: U65990MH1993PLC071003

### NOTICE NO. 11

#### Declaration of Income Distribution cum Capital Withdrawal ("IDCW") in Canara Robeco Mutual Fund Schemes:

Notice is hereby given that the Board of Trustees of Canara Robeco Mutual Fund has declared IDCW in the following schemes, subject to availability of distributable surplus:

Scheme Name	Investment Option	IDCW (₹ per unit)	Face Value (₹ per unit)	NAV Per Unit as on 27.05.2024 (₹)
Canara Robeco Corporate Bond Fund	Regular Plan - IDCW (Payout/Reinvestment) Option	0.29	10.00	11.5328
	Direct Plan - IDCW (Payout/Reinvestment) Option	0.31	10.00	12.2600
Canara Robeco Short Duration Fund	Regular Plan - Monthly IDCW (Payout/Reinvestment) Option	0.06	10.00	15.2741
	Direct Plan - Monthly IDCW (Payout/Reinvestment) Option	0.06	10.00	17.3829
Canara Robeco Conservative Hybrid Fund	Regular Plan - Monthly IDCW (Payout/Reinvestment) Option	0.10	10.00	13.4308
	Direct Plan - Monthly IDCW (Payout/Reinvestment) Option	0.10	10.00	16.3521
Canara Robeco Equity Hybrid Fund	Regular Plan - Monthly IDCW (Payout/Reinvestment) Option	0.69	10.00	98.9100
	Direct Plan - Monthly IDCW (Payout/Reinvestment) Option	0.60	10.00	127.5700

Pursuant to payment of dividend/IDCW, the NAV of the IDCW option of the schemes would fall to the extent of payout and statutory levy (if any).

Record Date for the purpose of distribution of dividend/IDCW is May 31, 2024, or the next business day if the record date happens to be a non-business day. All unit holders, under the abovementioned Plan/Option, whose names appear on the register of unit holders of the Scheme as on the record date, are eligible for the dividend/IDCW.

The Dividend/IDCW declared out of the Distributable Surplus of the abovementioned Schemes will be paid net of tax deducted at source (TDS) as applicable, to those unit holders whose names appear in the register of unit holders as on the Record Date.

Declaration of dividend/IDCW is subject to availability of distributable surplus on the record date/ex-dividend date.

In case the distributable surplus is less than the quantum of dividend/IDCW on the record date/ex-dividend date, the entire available distributable surplus in the Scheme/plan will be declared as dividend/IDCW.

SEBI circular no. SEBI/HO/IMD/DF3/CIR/P/2020/194 dated 5<sup>th</sup> October 2020 on review of Dividend option(s)/ Plan(s) in case of Mutual Fund Schemes shall be applicable for calculation of distributable surplus.

In view of individual nature of tax consequences, each investor is advised to consult his/her own professional financial/tax advisor.

Unit holders are requested to visit www.canararobeco.com to claim their Unclaimed Redemption & Dividend/IDCW amounts and follow the procedure prescribed therein.

For and on behalf of Canara Robeco Asset Management Company Ltd.  
 (Investment manager for Canara Robeco Mutual Fund)  
 Sd/-  
**Authorised Signatory**

Date: 28-05-2024  
 Place: Mumbai

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

# NEW DELHI TELEVISION LIMITED

CIN: L9211DL1988PLC033099  
 Regd. Off: W-17, 2<sup>nd</sup> Floor, Greater Kailash - I, New Delhi-110048  
 Phone: (91-11) 4157 7777, 2644 6666  
 E-mail: secretarial@ndtv.com; Website: www.ndtv.com

## NOTICE OF THE 36<sup>th</sup> ANNUAL GENERAL MEETING AND E-VOTING INFORMATION

NOTICE is hereby given that the 36<sup>th</sup> Annual General Meeting (AGM) of the Shareholders of New Delhi Television Limited will be held on Wednesday, June 26, 2024 at 12:00 p.m. through Video Conference (VC) / Other Audio Visual Means (OAVM) to transact the business, as set out in the Notice convening the AGM. The Company has already dispatched the Annual Report for the financial year 2023-24 along with the Notice convening the AGM, through electronic mode to the Shareholders whose email addresses are registered with the Company and / or Depositories in accordance with the Circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The Annual Report along with the Notice of the AGM is also available on the website of the Company at [www.ndtv.com](http://www.ndtv.com), and National Securities Depository Limited (NSDL) at [www.evoting.nsdl.com](http://www.evoting.nsdl.com), BSE Limited at [www.bseindia.com](http://www.bseindia.com) and National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com).

**Remote e-voting and e-voting during AGM**

Pursuant to the provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Shareholders are provided with the facility to cast their votes on all resolutions as set forth in the Notice convening the AGM using electronic voting system ('Remote e-voting') provided by NSDL. The voting rights of Shareholders shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on **Friday, June 14, 2024 ('Cut-off date')**.

The remote e-voting period commences on **Sunday, June 23, 2024 at 9.30 a.m. and will end on Tuesday, June 25, 2024 at 5.00 p.m.** During this period, the Shareholders may cast their vote electronically. The remote e-voting module shall be disabled by NSDL thereafter. Those Shareholders, who shall be present in the AGM through VC/OAVM and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The Shareholders who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Shareholder of the Company after the Notice has been sent electronically by the Company, and holds shares as on the Cut-off date, may obtain the login ID and password by sending a request to [evoting@ndtv.com](mailto:evoting@ndtv.com). However, if he/she is already registered with NSDL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

In case of any queries pertaining to e-voting, Shareholders may refer to the Frequently Asked Questions ('FAQs') and the e-voting manual available at download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com), or call on: 022 - 4886 7000 or send a request to Ms. Pallavi Mahatre, Senior Manager, NSDL at [evoting@nsdl.com](mailto:evoting@nsdl.com).

For New Delhi Television Limited  
 Sd/-  
**Parinita Bhutani Duggal**  
 Company Secretary & Compliance Officer

Place: New Delhi  
 Date: May 28, 2024

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as Genlink Pharma Investments Private Limited)  
 CIN: U74110MH2016PTC280765  
 Reg. Off: 401, 4th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai, 400705, Maharashtra, India. Ph: +91 22 6750 7000 Fax: +91 22 6750 7070 Email: [genlinkinfo@gmail.com](mailto:genlinkinfo@gmail.com) Website: [www.genlinkpharma.com](http://www.genlinkpharma.com)

## Extract of Standalone Unaudited Financial Results for the quarter ended 30th June, 2023

Particulars	Quarter ending	Corresponding Quarter for the	Previous Year
	30/06/2023	previous year ended 30/06/2022	Ended 31st March 2023
	(Unaudited)	(Unaudited)	(Audited)
Total income from operations	1,184,356	1,178,399	4,793,035
Net Profit / (Loss) for the period (before tax and/or Exceptional and/or Extraordinary items)	58,892	305,945	1,309,190
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	58,892	305,945	1,309,190
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	-11,108	241,922	1,065,190
Total Comprehensive income for the period (comprising profit/loss) for the period (after tax) and other comprehensive income (after tax)	-11,108	241,922	1,065,190
Paid Equity Share Capital	100,000	100,000	100,000
Reserves (excluding Revaluation Reserve)	4,952,778	4,140,618	4,963,886
Securities premium account	-	-	-
Net Worth	5,052,778	4,240,618	5,063,886
Paid up debt Capital/Outstanding Debt	24,251,047	276,138,157	24,614,531
Outstanding Redeemable Debentures	250,000,000	250,000,000	250,000,000
Debt Equity Ratio	54	124	54
Earnings Per Share (of 10/- each) (for continuing and discontinued operations)	(1.11)	24.19	106.52
Diluted:	(1.11)	24.19	106.52
Capital Redemption Reserve	-	-	-
Debt Redemption Reserve	-	-	-
Debt Service Coverage Ratio	0.00	0.00	0.00
Interest Service Coverage Ratio	1.64	1.59	1.62

**Notes:**

- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchange under Regulation 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) (www.bseindia.com) and the listed entity (<https://genlinkpharma.com/investor-relations.html>)
- The above results were approved by the Board of Directors at their meeting held on 27th May, 2024.
- For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Bombay Stock Exchange and can be accessed on [www.bseindia.com](http://www.bseindia.com) and can be accessed on Company's website (<https://genlinkpharma.com/investor-relations.html>)
- As there has been no change in accounting policies, hence no impact on net profit/ loss, total comprehensive income or any other relevant financial items(s).

For Genlink Pharma Solutions Private Limited  
 Sd/-  
**Anand Shah**  
 Director  
 DIN: 00597145

Sd/-  
**Susheel Koul**  
 Managing Director  
 DIN: 00925887

Date : 27.05.2024  
 Place: Navi Mumbai

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as Genlink Pharma Investments Private Limited)  
 CIN: U74110MH2016PTC280765  
 Reg. Off: 401, 4th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai, 400705, Maharashtra, India. Ph: +91 22 6750 7000 Fax: +91 22 6750 7070 Email: [genlinkinfo@gmail.com](mailto:genlinkinfo@gmail.com) Website: [www.genlinkpharma.com](http://www.genlinkpharma.com)

## Extract of Standalone Unaudited Financial Results for the quarter ended 31st December, 2023

Particulars	Quarter ending	Corresponding Quarter for the	Previous Year
	31/12/2023	previous year ended 31/12/2022	Ended 31st March 2023
	(Unaudited)	(Unaudited)	(Audited)
Total income from operations	1,187,095	1,184,935	4,793,035
Net Profit / (Loss) for the period (before tax and/or Exceptional and/or Extraordinary items)	-157,869	371,049	1,309,190
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	-157,869	371,049	1,309,190
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	-95,265	307,027	1,065,190
Total Comprehensive income for the period (comprising profit/loss) for the period (after tax) and other comprehensive income (after tax)	-95,265	307,027	1,065,190
Paid Equity Share Capital	100,000	100,000	100,000
Reserves (excluding Revaluation Reserve)	4,718,656	4,749,146	4,963,886
Securities premium account	-	-	-
Net Worth	4,818,656	4,849,146	5,063,886
Paid up debt Capital/Outstanding Debt	22,306,689	274,807,405	24,614,531
Outstanding Redeemable Debentures	250,000,000	250,000,000	250,000,000
Debt Equity Ratio	56.51	56.67	54.23
Earnings Per Share (of 10/- each) (for continuing and discontinued operations)	(9.53)	30.70	106.52
Diluted:	(9.53)	30.70	106.52
Capital Redemption Reserve	-	-	-
Debt Redemption Reserve	-	-	-
Debt Service Coverage Ratio	0.00	0.00	0.00
Interest Service Coverage Ratio	0.93	0.24	1.62

**Notes:**

- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchange under Regulation 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) (www.bseindia.com) and the listed entity (<https://genlinkpharma.com/investor-relations.html>)
- The above results were approved by the Board of Directors at their meeting held on 27th May, 2024.
- For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Bombay Stock Exchange and can be accessed on [www.bseindia.com](http://www.bseindia.com) and can be accessed on Company's website (<https://genlinkpharma.com/investor-relations.html>)
- As there has been no change in accounting policies, hence no impact on net profit/ loss, total comprehensive income or any other relevant financial items(s).

For Genlink Pharma Solutions Private Limited  
 Sd/-  
**Anand Shah**  
 Director  
 DIN: 00597145

Sd/-  
**Susheel Koul**  
 Managing Director  
 DIN: 00925887

Date : 27.05.2024  
 Place: Navi Mumbai

# OXYZO FINANCIAL SERVICES LIMITED

(FORMERLY KNOWN AS OXYZO FINANCIAL SERVICES PRIVATE LIMITED)  
 Registered office: Shop No. G-22C (UGF) D-1 (K-84) Green Park Main, New Delhi-110016  
 Tel. No: 011-47640758, Website: [www.oxyzo.in](http://www.oxyzo.in), CIN: U65929DL2016PLC036174

## Extract of Standalone & Consolidated Financial Results for the Quarter and Year Ended 31 March 2024

Sl. No.	Particulars	Standalone		Consolidated	
		Quarter ended		Year ended	
		31 March 2024 (Reviewed)	31 March 2023 (Reviewed)	31 March 2024 (Reviewed)	31 March 2023 (Reviewed)
1	Total Income from Operations	23,745.40	22,193.31	16,854.89	85,313.57
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	10,259.50	10,245.08	8,427.48	38,324.44
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	10,259.50	10,245.08	8,427.48	38,324.44
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	7,659.04	7,442.33	6,305.19	28,567.89
5	Total comprehensive income for the period (comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (After Tax)	7,659.04	7,442.33	6,305.19	28,567.89
6	Paid up Equity Share Capital	5,367.86	5,367.86	5,367.87	5,367.86
7	Instruments entirely equity in nature	1,438.29	1,438.29	1,438.29	1,438.29
8	Reserves (excluding Revaluation Reserve)	2,52,139.88	2,44,162.05	2,22,690.90	2,52,139.88
9	Securities Premium Account	1,89,180.35	1,89,180.35	1,89,180.35	1,89,180.35
10	Net worth	2,58,946.03	2,50,968.20	2,29,497.05	2,58,946.03
11	Paid up Debt Capital/Outstanding Debt	4,59,706.94	4,01,730.91	3,12,569.61	4,59,706.94
12	Debt Equity Ratio	1.78	1.55	1.36	1.78
13	Earnings per share (nominal value of share Rs. 10/- each): Basic (in Rupees) Diluted (in Rupees)	11.25 10.60	10.56 9.94	9.26 8.85	41.97 39.55

**Notes:**

- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly ended financial results are available on the websites of the BSE Limited i.e. [www.bse](http://www.bseindia.com)